3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
18
Triple Negative Breast Neoplasms
16
Carcinoma, Transitional Cell
4
Neoplasm Metastasis
3
Carcinoma, Non-Small-Cell Lung
3
Salivary Gland Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Metastatic Urothelial Cancer
1
Meningeal Carcinomatosis
1
Lung Diseases
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
trastuzumab deruxtecan
1
taxane
1
sacituzumab govitecan
1
liposomal doxorubicin
1
eribulin
1
Vinorelbine
1
Paclitaxel
1
Gemcitabine
1
Epirubicin
1
Docetaxel
1
Cyclophosphamide
1
Carboplatin
1
Capecitabine
1
Anthracyclines
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
HER2-negative Breast Cancer
×
sacituzumab govitecan
×
Clear all
NCT06102824
2024-11-25
ORIENTA
Guangdong Provincial People's Hospital
Phase 2
Recruiting
252 enrolled